spacer
home > ebr > summer 2004 > the ipo window reopens - are you ready?
PUBLICATIONS
European Biopharmaceutical Review

The IPO Window Reopens - Are you Ready?

Whisper it quietly, but the IPO window may just have reopened for European biotechs. Ark Therapeutics' flotation in March this year has led to a spate of similar launches of biotech stocks onto the public markets after a dearth of opportunities in recent years. The position undoubtedly remains volatile. Only the best companies will be allowed to list and, as ever, due diligence will be key. This article looks at the importance of legal due diligence in the context of an impending IPO and asks are you ready to take advantage of the IPO window - which may yet prove shortlived.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Patrick Martin, Partner and Martin Finnegan, Senior Solicitor at McGrigors

Patrick Martin is a Partner and Corporate and Commercial Lawyer at McGrigors, with a particular emphasis on the health care and life sciences fields, acting for both investors and companies. He has advised on numerous technology start-ups and spin-outs, fundraisings and private placements for biotech companies and IPOs. Patrick has specialised in private equity work for over 14 years.


Martin Finnegan is a senior Corporate Solicitor at McGrigors and part of the firm's public equity group. Martin has advised on numerous IPOs and public equity issues acting for sponsors and companies, and is a member of the legal committee of the Quoted Companies Alliance (QCA).

spacer
Patrick Martin
spacer
spacer
spacer
Martin Finnegan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Launches Partner Program to Team with Clinical Research Organizations (CROs) Committed to Improving Clinical Trials with Patient-Centric Technology

PHILADELPHIA August 12, 2019: Signant Health (signanthealth.com), a leading provider of technology for clinical research, today launches the Signant Health Partner Program, a significant investment the company is making to enable clinical research organizations (CROs) to better serve sponsors in the areas of Patient Data, Patient Experience, Clinical Supplies, and Endpoint Quality Solutions. By becoming a Signant Partner, CROs will benefit from new commercial and operational advantages that only come with membership.
More info >>

White Papers

Clinical Research in Spain

BioClever

This whitepaper is on clinical research in Spain, giving a general outline of the main characteristics of research in this country and an overview of the applicable regulations, along with the reasons why Spain is a good place to do research.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement